江苏晟斯生物制药

Suns Biopharma is a clinical-stage Chinese biotechnology company dedicated to the development of innovative therapies for rare diseases, with a primary focus on hemophilia. The company has established a robust pipeline of long-acting and ultra-long-acting recombinant coagulation factors designed to improve the quality of life for patients by reducing injection frequency. Its lead programs include long-acting Factor VIII and Factor IX treatments that utilize advanced protein engineering and fusion technology. Suns Biopharma operates integrated R&D and manufacturing facilities in Nanjing, Beijing, and Shanghai to support its transition into a commercial-stage biopharmaceutical entity.